Most Recent Articles by Leslie Burgess, MA
Although cytogenetic abnormalities that arise during the course of CML are prevalent in later stages of the disease and are associated with a poorer prognosis, as many as 10% to 12% of patients exhibit ACAs at diagnosis.
CONTINUUM suggests that maintenance therapy with lenalidomide is an effective way for prolonging progression-free survival without affecting potential subsequent lines of therapy.
The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
Cancer Therapy Advisor interviewed Keith Flaherty, MD, about recent findings regarding targeted therapies for melanoma.
More Articles by Leslie Burgess, MA
Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of NeurotoxicityAug 25,2015
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Axillary Node Management for Breast Cancer: Is Less More?
- Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer
- Potentially Inappropriate Medications May Shorten Survival Among Elderly Patients With Lymphoma
- Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma
- The Potential of Radium-223 in Modern Prostate Cancer Treatment
- Colorectal Cancer Screening: Utility of Septin-9 Assays
- Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC
- Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer
- Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
- Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research